A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH THEIR LIPID-MODIFYING THERAPY IN SOUTH KOREA AND TAIWAN

Background: Alirocumab (ALI), a fully human monoclonal antibody to PCSK9, has been shown to provide significant reductions in LDL-C. Data about its efficacy and safety in patients from South Korea and Taiwan is limited. Methods: Patients (n=199) with hypercholesterolemia at high cardiovascular risk